AP804A - APO-B-secretion/MTP inhibitory amides. - Google Patents
APO-B-secretion/MTP inhibitory amides. Download PDFInfo
- Publication number
- AP804A AP804A APAP/P/1997/001145A AP9701145A AP804A AP 804 A AP804 A AP 804A AP 9701145 A AP9701145 A AP 9701145A AP 804 A AP804 A AP 804A
- Authority
- AP
- ARIPO
- Prior art keywords
- inhibitors
- compounds
- crc10
- alkyl
- crc4
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Abstract
This invention is directed to compounds of the formula or the stereoisomers, pharmaceutically-acceptable salts and hydrates thereof. The compounds are Apo B/MTP inhibitors and are useful in the treatment of various disorders and conditions such as atherosclerosis, pancreatitis, obesity, hypercholesteremia, hypertriglyceridemia, hyperlipidemia, and diabetes. The compounds of this invention are also useful in combination with other pharmaceutical agents including cholesterol biosynthesis inhibitors and cholesterol absorption inhibitors, especially HMG-CoA reductase inhibitors and HMG-CoA synthase inhibitors; HMG-CoA reductase gene expression inhibitors; CETP inhibitors; bile acid sequestrants; fibrates; cholesterol absorption inhibitors; ACAT inhibitors, squalene synthetase inhibitors, ion-exchange resins, anti-oxidants and niacin. This invention is also directed to intermediates and processes useful in the preparation of compounds of formula (I).
Description
Apo B-SECRETION/MTP INHIBITORY AMIDES
Field Of The Invention
This invention relates to compounds which are inhibitors of microsomal triglyceride transfer protein (MTP) and/or apolipoprotein B (Apo B) secretion and which are, accordingly, useful for the prevention and treatment of atherosclerosis and its clinical sequelae, for lowering serum lipids, and in the prevention and treatment of related diseases. The invention further relates to pharmaceutical compositions comprising these compounds and to methods of treating atherosclerosis, obesity, and related diseases and/or conditions with said compounds, either alone or in combination with other medicaments, including lipid lowering agents. Further still, the invention relates to certain processes and intermediates related thereto which are useful in the preparation of the compounds of the instant invention.
Background Of The Invention
Microsomal triglyceride transfer protein catalyzes the transport of triglyceride, cholesteryl ester, and phospholipids and has been implicated as a putative mediator in the assembly of Apo B-containing lipoproteins, biomolecules which contribute to the formation of atherosclerotic lesions. Specifically, the subcellular (lumen of the microsomal fraction) and tissue distribution (liver and intestine) of MTP have led to speculation that it plays a role in the assembly of plasma lipoproteins, as these are the sites of plasma lipoprotein assembly. The ability of MTP to catalyze the transport of triglyceride between membranes is consistent with this speculation, and suggests that MTP may catalyze the transport of triglyceride from its site of synthesis in the endoplasmic reticulum membrane to nascent lipoprotein particles within the lumen of the endoplasmic reticulum.
Compounds which inhibit MTP and/or otherwise inhibit Apo B secretion are accordingly useful in the treatment of atherosclerosis and other conditions related thereto. Such compounds are also useful in the treatment of other diseases or conditions in which, by inhibiting MTP and/or Apo B secretion, serum cholesterol and triglyceride levels may be reduced. Such conditions may include, for example, hypercholesterolemia, hypertriglyceridemia, pancreatitis, and obesity; and hypercholesterolemia, hypertriglyceridemia, and hyperlipidemia associated with pancreatitis, obesity, and diabetes. For a detailed discussion, see for example, Wetterau et al„ Science, 258, 999-1001, (1992), Wetterau et al., Biochem. Biophys. Acta., 875, 610-617 (1986), European patent application publication No. 0 584 446 A2, and European patent application publication No. 0 643 057 A1 the latter of which discloses certain compounds of the generic formulae
which have utility as inhibitors of MTP.
Summary Of The Invention
The instant invention relates to compounds which are Apo B-secretion/MTP inhibitors represented by the structural formula (I), including the stereoisomers and the pharmaceutically acceptable salts and hydrates thereof,
wherein G is selected from:
(a) a phenyl or heterocyclic ring wherein said heterocyclic ring contains a total of from 3 to 14 ring atoms, wherein said heterocyclic ring incorporates a total of from 1 to 4 ring heteroatoms selected independently from oxygen, nitrogen, and sulfur, wherein the individual rings of said heterocyclic ring may be independently saturated, partially saturated or aromatic, and wherein each of said phenyl or heterocyclic rings may have optionally from 1 to 4 substituents selected independently from halogen, hydroxy, cyano, nitro, oxo, thioxo, aminosulfonyl, phenyl, phenoxy, phenylthio, benzyl, benzoyl, benzyloxy, (CrC10)alkyl, (Cr C4)perfluoroalkyl, (C1-C10)alkoxy, (Ci-C4)perfluoroalkoxy, {C1-C50)alkoxycarbonyl, (Ct-CuOalkylthio, (Ci-C10)alkylamino, di(C1-Ci0)alkylamino, (Cr C10)alkylaminocarbonyl, di(CrC10)alkylaminocarbonyl, diiCrCioJalkylaminoiCr C10)alkoxy, (CrC10)acyl, (C^-C^perfluoroacyl, (CrCi0)acyloxy, (CrC-ioJacyloxyiCr C10)alkyl, (C-rCeJacylamino and (CrCeJperfluoroacylamino; (b) -CH2CN,
(d) (C2-C12)alkyl or (C2-C12)perfluoroalkyl wherein each of said (C2-Ci2)alkyl and (C2-C12)perfluoroalkyl is substituted optionally with from 1-3 substituents selected independently from: (1) phenyl, halogen, nitro, cyano, hydroxy, -NR1R2, -OCOR3, (Ci-C4)alkoxy, (CrC4)perfluoroalkoxy, (CrC4)thioalkoxy or (CrC^perfluorothioalkoxy, where R1 and R2 in the definition of -NR1R2 are each selected independently from hydrogen, formyl, phenyl, benzyl, benzoyl, (C3-C8)cycloalkyl, (C3-C8)cycloalkenyl, (CrC4)alkyl, (C1-C4)perfluoroalkyl, (CrC10)alkoxycarbonyl, (Cr C6)acyl, (C-|-C6)perfluoroacyl, aminocarbonyl, (CrC10)alkylaminocarbonyl, di(Cr C10)alkylaminocartx3nyl, aminosulfonyl, (CrC^alkylaminosulfonyl, di(Cr C4)alkylaminosulfonyl, (CrCJperfluoroalkylaminosuIfonyl, (Cr
C4)perfluoroalkylaminosulfonyl, difCrC^alkylsulfonyl, and (C-|- C4)perfluoroalky!sulfonyl, or where R1 and R2, taken together with the nitrogen atom to which they are attached, form a saturated, partially-saturated or aromatic heterocyclic ring, wherein said heterocyclic ring contains a total of from 3 to 14 ring atoms and incorporates optionally an additional 1 to 4 ring heteroatoms selected independently from oxygen, nitrogen and sulfur, wherein said heterocyclic ring may have optionally from 1 to 4 substituents selected independently from halogen, hydroxy, cyano, nitro, oxo, thioxo, aminosulfonyl, phenyl, phenoxy, phenylthio, benzyl, benzoyl, benzyloxy, (Ci-C10)alkyl, (CvCJperfluoroalkyl, (CrCio)alkoxy, (Cr C4)perfluoroalkoxy, (CrCi0)alkoxycarbonyl, (CrCio)alkylthio, (CrC10)alkylamino, di(CrCio)alkylamino, (CrC10)alkylaminocarbonyl, di(Ci-Ci0)alkylaminocarbonyl, diiCrC^alkylaminoiC-j-CicOalkoxy, (CrC10)acyl, (Ci-C10)perfluoroacyl, (Cr C10)acylamino, (CrC10)acyloxy, and (C1-Ci0)acyloxy(C1-C10)alkyl, where R3 is selected from -NR1R2, phenyl, (CrC10)alkyl, (Cr C4)perfluoroalkyl, (CrC6)alkoxy and (CrC^perfluoroalkoxy, f (2) (C3-C8)cycloalkyl or (C3-C8)cycloalkenyl wherein each of said (C3-C8)cycloalkyl and (C3-C8)cycloalkenyl may have optionally from 1 to 4 substituents selected independently from halogen, hydroxy, cyano, nitro, oxo, thioxo, aminosulfonyl, phenyl, phenoxy, phenylthio, benzyl, benzoyl, benzyloxy, (C-i-Ci0)alkyl, (CrC4)perfluoroalkyl, (C1-C10)alkoxy, (CrC4)perfluoroalkoxy, (Cr Ci0)alkoxycarbonyl, (C1-C10)alkylthio, (CrC10)alkylamino, di(C1-C10)alkylamino, (Cr C10)alkylaminocarbonyl, di(CrC10)alkylaminocarbonyl, diiCrCioJalkylaminofCr C10)alkoxy, (CrCi0)acyl, (C-,-C10)perfluoroacyl, (C1-C10)acylamino, (Cr Cio)perfluoroacylamino, (CrC10)acyloxy, and (CrC^JacyloxyCC-i-CioJalkyl, and (3) a saturated, partially-saturated or aromatic heterocyclic ring containing a total of from 3 to 14 ring atoms, wherein said heterocyclic ring incorporates a total of from 1 to 4 ring heteroatoms selected independently from oxygen, nitrogen and sulfur, wherein said heterocyclic ring may have optionally from 1 to 4 substituents selected independently from halogen, hydroxy, cyano, nitro, oxo, thioxo, aminosulfonyl, phenyl, phenoxy, phenylthio, benzyl, benzoyl, benzyloxy, (C-,-C10)alkyl, (CrC4)perfluoroalkyl, (CrCio)alkoxy, (CrC4)perfluoroalkoxy, (Cr C10)alkoxycarbonyl, (Ci-C10)alkylthio, (CrC10)alkylamino, di(Ci-C10)alkylamino, (Cr C10)alkylaminocarbonyl, di(CrC10)alkylaminocarbonyl, di(Ci-C10)alkylamino(C-i-C10)alkoxy, (CrCi0)acyl, (CrC^perfluoroacyl, (Οι·Όιο)3εΥΐθπιϊηο, (Cr C10)perfluoroacylamino, (CrC10)acyloxy, and (C1-C10)acyloxy(C1-C10)alkyl, provided that (C2-C12)alkyl does not include unsubstituted allyl; (e) (C3-C8)cycloalkyl or (C3-C8)cycloalkenyl wherein each of said (C3-C8)cycloalkyl and (C3-C8)cycloalkenyl may have optionally from 1 to 4 substituents selected independently from halogen, hydroxy, cyano, nitro, oxo, thioxo, aminosulfonyl, phenyl, phenoxy, phenylthio, benzyl, benzoyl, benzyloxy, (Ci-C10)alkyl, (Cr C4)perfluoroalkyl, (C1-C10)alkoxy, (C^C^perfluoroalkoxy, (CrC10)alkoxycart)onyl, (CrC10)alkylthio, (CrC^Jalkylamino, di(CrC10)alkylamino, (Cr
Cio)alkylaminocarbonyl, di(Ci-C10)alkylaminocarbonyl, di(C1-C50)alkylamino(C1-Ci0)alkoxy, (CrC10)acyl, (CrC10)perfluoroacyl, (CrC10)acylamino, (Cr C10)perfluoroacylamino, (CrC10)acyloxy, and (C1-C10)acyloxy(C1-C10)alkyl; and (f) -(CH2)nCOR4, where R4 is selected from hydroxy, phenyl, -NR1R2, (CrC4)alkyl, (Ci-C4)perfluoroalkyl, (CrC4)alkoxy, (C^-C^perfluoroalkoxy, (C3-C8)cycloalkyl, and (C3-C8)cycloalkenyl, where n is an integer from 1 to 4. A preferred subgroup of the compounds of formula (I) and the stereoisomers, pharmaceutically acceptable salts and hydrates thereof, includes those compounds wherein G is selected from: (a) a phenyl or heterocyclic ring wherein said heterocyclic ring contains a total of from 3 to 7 ring atoms, wherein said heterocyclic ring incorporates a total of from 1 to 4 ring heteroatoms selected independently from oxygen, nitrogen, and sulfur, wherein said heterocyclic ring may be saturated, partially saturated or aromatic, and wherein each of said phenyl or heterocyclic rings may each have optionally from 1 to 4 substituents selected independently from halogen, hydroxy, phenyl, benzyl, benzoyl, benzyloxy, (CrCio)alkyl. (CrC4)perfluoroalkyl, (CrC-t0)alkoxy, (Cr C4)perfluoroalkoxy, (C-|-e10)alkoxycarbonyl, (CrC10)alkylthio, (CrC10)alkylamino, di(CrCi0)alkylamino, (CrC10)alkylaminocarbonyl, di(CrC10)alkylaminocarbonyl, dKCrC^alkylaminoCCrC^alkoxy, (CrC10)acyl, (Ci-C10)perfluoroacyi, (C-r Ce)acylamino, (CrCe)perfiuoroacylamino, (C1-C10)acyloxy, and (CrCioJacyloxyiCr Cio)alkyl; (b) (C2-C12)alkyl wherein said (C2-Ci2)alkyl is substituted optionally with from 1-3 substituents selected from: (1) phenyl, halogen, cyano, hydroxy, -NR1R2, -OCOR3, (Ci-C4)alkoxy, or (Ci-C4)perfluoroalkoxy, where R3 is selected from -NR1R2, (CrC4)alkyl and (C1-C4)perfluoroalkyl, (2) (C3-C6)cycloalkyl or (C3-C6)cycloalkenyl wherein each of said (C3-C6)cycloalkyl and (C3-C6)cycloalkenyl may optionally have from 1 to 4 substituents selected independently from hydroxy, (CrC4)alkyl, (CrC4)alkoxy, and (C-|-C4)alkoxycarbonyl, and (3) a saturated, partially-saturated or aromatic heterocyclic ring containing a total of from 3 to 6 ring atoms, wherein said heterocyclic ring incorporates a total of from 1 to 4 ring heteroatoms selected independently from oxygen, nitrogen and sulfur, wherein said heterocyclic ring may have optionally from 1 to 4 substituents selected independently from halogen, hydroxy, phenyl, benzyl, benzoyl, benzyloxy, (Cf-C10)alkyl, (CrC4)perfluoroalkyl, (C1-C10)alkoxy, (CrCioJalkoxycarbonyl, (Cr C10)alkylthio, (Ci-Cio)alkylamino, di(CrC10)alkylamino, (C1-C10)alkylaminoci3rbonyl, di(C-,-Cio)alkylaminocarbonyl, di(Ci-C1o)alkylamino(C1-C10)alkoxy, (Cr C4)perfluoroalkoxy, (C-i-Cio)acyl, (CrC10)acylamino, (C1-C10)perfluoroacylamino, (Cr C10)acyloxy, and (C1-C10)acyloxy(C1-C10)alkyl; provided that (C2-C12)alkyl does not include unsubstituted allyl, (c) (C3-C6)cycloalkyl or (C3-C6)cycloalkenyl wherein each of said (C3-C6)cycloalkyl and (C3-C6)cycloalkenyl may have optionally from 1 to 4 substituents selected independently from hydroxy, (CrC4)alkyl, (CrC4)alkoxy, (CrCwJacylamino, (Cr C10)perfluoroacylamino and (CrC4)alkoxycarbonyl; and (d) -(CH2)nCOR4, where R4 is selected from hydroxy, phenyl, -NR1R2, (CrC4)alkyl, (CrC^perfluoroalkyl, (CrC4)alkoxy, (C-,-C4)perfIuoroalkoxy, (C3-C6)cycloalkyl, and (C3-C6)cycloalkenyl, where n is an integer from 1 to 4.
More particularly preferred of the compounds of formula (I) including the stereoisomers, pharmaceutically acceptable salts and hydrates thereof, are those compounds of the subgroup wherein G is selected from: (a) (C2-C12)alkyl, wherein said (C2-C12)alkyl is substituted optionally with a group selected from phenyl, halogen, cyano, hydroxy, (CrC4)alkoxy, or a saturated, partially-saturated or aromatic heterocyclic ring selected from thienyl, pyrazolyl, pyrrolidinyl, pyrrolyl, furanyl, thiazolyl, isoxazolyl, imidazolyl, triazolyl, tetrahydropyranyl, pyridyl, and pyrimidyl, wherein each of said heterocyclic rings may have optionally from 1 to 3 substitutents selected independently from halogen, (CrC4)acyl, (CrC4)perfIuoroacyl, (CrC4)alkyl, (CrCJperfluoroalkyl, (CrC4)alkoxy, (Ci-C4)alkylaminocarbonyl, and (C1-C4)acylamino; provided that (C^-C^Jalkyl does not include unsubstituted allyl; (b) -(CH2)nNR1R2, where n is an integer from 2 to 4; and (c) -(CH2)nCOR4, where n is 1 or 2.
The following compounds of formula (I), including the stereoisomers and the pharmaceutically acceptable salts and hydrates thereof, listed hereinbelow together with their corresponding IUPAC chemical names, are especially preferred wherein G is selected from: -CH2COOH, (6-i(4’-Trifiuoromethvlbiphenvl-2-carbonvn-amino]-3.4-dihvdro-1H-isoauinolin-2-viy-acetic acid: -(CH2)4CH3, 4,-Irifluoromethylbiphenyl-2-carboxylic acid-(n-pentyl-1.2.3.4-tetrahydroisoauinolin-g-yl)-amide; -(CH2)3OCH3, 4,-Trifluoromethylbiphenyl-2-carboxylic acid-r2-f3-methoxypropyl)-1.2.3.4-tetrahvdroisoquinolin-6-yi]-amide: -(CH2)2OCH3, 4’-Trifluoromethylbipheny[-2-carboxylic acid-[2-(2-methoxvethvl)-1.2.3.4-tetrahvdroisoquinolin-6-yQ-amide: -(CH2)2OCH2CH3, 4’-TrifluoromethylbiDhenyl-2-carboxylic acid-r2-I2-ethoxyethvl)-1.2.3.4-tetrahydroisoquinolin-6-yl]-aro!de: -(CH2)2CN, 4’-Trifluoromethylbiphenyl-2-carboxylic acid-[2-(2-cvanoethyl)-1.2.3.4-tetrahydroisoauinolin-6-yll-amide: -(CH2)2OCOCH3,
Acetic acid 2-(6-[f4’-trifluoromethylbiphenyl-2-carbonyl)-amino]-3.4-dihydro-1 H-isoquinolin-2-yl}-ethyl ester: -(CH2}2OCON(CH3)2,
Dimethvlcarbamic acid 2-{6-[(4’-trifluoromethylbiphenyl-2-carbonvl)-amino]-3jL· dihvdro-1 H-isoauinolin-2-yl}-ethyl ester; -(CH2)2NH2, t 4’-Trifluoromethylbiphenyl-2-carboxylic acid-[2-(2-aminoethyn-1.2.3.4-tetrahydroisioquinolin-6-yl]-amide: -(CH2)2NHCOCH3, 4.’-Trifluoromethylbiphenyl-2-carboxylic acid-[2-(2-acetylaminoethyl)-1.2.3,4-tetrahydroisoauinolin-6-yn-amide; -(CH2)2CON(CH3)2, 4’-Trif1uoromethvlbiphenvl-2-carboxviic acid-[2-(2-dimethytcarbamoylethyl)-1.2.3.4-tetrahydroisoquinolin-6-yQ-amide: -CH2CON(CH3)2, 4’-TrifluorQmethylbiphenyl-2-carboxylic acid-f 2-dimethylcarbamoylmethvl-1.2.3.4-te.trahvdroisoauinolin-6-yl)-amide: -CH2CON(CH2CH3)2,
Claims (1)
- Original document published without claims.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3230796P | 1996-11-27 | 1996-11-27 | |
PCT/IB1997/001368 WO1998023593A1 (en) | 1996-11-27 | 1997-11-03 | Apo b-secretion/mtp inhibitory amides |
Publications (2)
Publication Number | Publication Date |
---|---|
AP9701145A0 AP9701145A0 (en) | 1998-01-31 |
AP804A true AP804A (en) | 2000-01-28 |
Family
ID=21864233
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
APAP/P/1997/001145A AP804A (en) | 1996-11-27 | 1997-11-20 | APO-B-secretion/MTP inhibitory amides. |
Country Status (34)
Country | Link |
---|---|
US (1) | US6121283A (en) |
EP (1) | EP0944602A1 (en) |
JP (1) | JP3270764B2 (en) |
KR (1) | KR100334567B1 (en) |
CN (2) | CN1238764A (en) |
AP (1) | AP804A (en) |
AR (1) | AR010309A1 (en) |
AU (1) | AU716151B2 (en) |
BG (2) | BG108830A (en) |
BR (1) | BR9714364A (en) |
CA (1) | CA2272719C (en) |
CZ (1) | CZ292160B6 (en) |
DZ (1) | DZ2358A1 (en) |
EA (1) | EA001539B1 (en) |
GT (1) | GT199700122A (en) |
HN (1) | HN1997000144A (en) |
HR (1) | HRP970642A2 (en) |
ID (1) | ID18995A (en) |
IL (1) | IL129744A0 (en) |
IS (1) | IS5040A (en) |
MA (1) | MA26451A1 (en) |
NO (1) | NO312760B1 (en) |
NZ (1) | NZ335162A (en) |
OA (1) | OA11050A (en) |
PA (1) | PA8441601A1 (en) |
PE (1) | PE17199A1 (en) |
SK (1) | SK65499A3 (en) |
TN (1) | TNSN97193A1 (en) |
TR (1) | TR199901180T2 (en) |
TW (1) | TW502023B (en) |
UY (1) | UY24789A1 (en) |
WO (1) | WO1998023593A1 (en) |
YU (1) | YU23499A (en) |
ZA (1) | ZA9710641B (en) |
Families Citing this family (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6262277B1 (en) | 1994-09-13 | 2001-07-17 | G.D. Searle And Company | Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
MX9709914A (en) * | 1995-06-07 | 1998-03-31 | Pfizer | BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION. |
GB9708805D0 (en) | 1997-05-01 | 1997-06-25 | Smithkline Beecham Plc | Compounds |
US5968950A (en) * | 1997-06-23 | 1999-10-19 | Pfizer Inc | Apo B-secretion/MTP inhibitor hydrochloride salt |
GB9810876D0 (en) | 1998-05-20 | 1998-07-22 | Smithkline Beecham Plc | Compounds |
AU4543899A (en) | 1998-06-08 | 1999-12-30 | Advanced Medicine, Inc. | Multibinding inhibitors of microsomal triglyceride transferase protein |
SK4782001A3 (en) | 1998-10-08 | 2001-11-06 | Smithkline Beecham Plc | Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) |
GB9826412D0 (en) | 1998-12-03 | 1999-01-27 | Glaxo Group Ltd | Chemical compounds |
IL143944A0 (en) * | 1998-12-23 | 2002-04-21 | Searle Llc | Combinations for cardiovascular indications |
BR9916486A (en) * | 1998-12-23 | 2002-02-05 | Searle Llc | Combinations of bile acid transport inhibitors in the ileum and cholesterol ester transfer protein inhibitors for cardiovascular indications |
DE19929012A1 (en) * | 1999-06-25 | 2000-12-28 | Bayer Ag | Synergistic drug combination, especially for treating cardiovascular diseases associated with metabolic disorders, comprising bi- or tricyclic aza-heterocyclic MTP inhibitor and metabolically active drug |
DE19929031A1 (en) * | 1999-06-25 | 2000-12-28 | Bayer Ag | Synergistic drug combination, especially for treating cardiovascular diseases associated with metabolic disorders, comprising bi- or tricyclic aza-heterocyclic MTP inhibitor and lipid metabolism regulator or vitamin |
DE19929065A1 (en) * | 1999-06-25 | 2000-12-28 | Bayer Ag | Synergistic drug combination, especially for treating cardiovascular diseases associated with metabolic disorders, comprising bi- or tricyclic aza-heterocyclic MTP inhibitor and HMG-CoA reductase inhibitor |
AU6824700A (en) * | 1999-07-20 | 2001-02-05 | Novartis Ag | Organic compounds |
CO5271688A1 (en) * | 1999-11-10 | 2003-04-30 | Pfizer Prod Inc | USE OF APOLIPROTEIN B AND / OR SECRETION INHIBITOR OF MICROSMAL TRIGLICERID TRANSFER PROTEIN |
IL139450A0 (en) * | 1999-11-10 | 2001-11-25 | Pfizer Prod Inc | Methods of administering apo b-secretion/mtp inhibitors |
CA2324801A1 (en) * | 1999-11-10 | 2001-05-10 | Andrew Gordon Swick | Use of apo b secretion/mtp inhibitors and anti-obesity agents |
CA2324800A1 (en) * | 1999-11-10 | 2001-05-10 | Mary Anne Hickman | Use of apo b secretion/mtp inhibitors |
WO2001053260A1 (en) * | 2000-01-18 | 2001-07-26 | Novartis Ag | Carboxamides useful as inhibitors of microsomal triglyceride transfer protein and of apolipoprotein b secretion |
MXPA02008797A (en) * | 2000-03-14 | 2005-09-08 | Actelion Pharmaceuticals Ltd | 1,2,3,4 tetrahydroisoquinoline derivatives. |
WO2001077077A1 (en) * | 2000-04-10 | 2001-10-18 | Novartis Ag | Substituted (hetero)aryl carboxamide derivatives as microsomal triglyceride transfer protein (mtp) and apolipoprotein b (apo b) secretion |
GB0013346D0 (en) * | 2000-06-01 | 2000-07-26 | Glaxo Group Ltd | Therapeutic benzamide derivatives |
GB0013383D0 (en) * | 2000-06-01 | 2000-07-26 | Glaxo Group Ltd | Therapeutic benzamide derivatives |
AU2001277728A1 (en) * | 2000-08-10 | 2002-02-25 | Tanabe Seiyaku Co., Ltd. | Biphenylcarboxamidoisoindoline compounds, processes for the preparation of the same and intermediates for the synthesis thereof |
WO2002014276A1 (en) * | 2000-08-10 | 2002-02-21 | Tanabe Seiyaku Co., Ltd. | Benzoylaminoisoindoline compounds, processes for the preparation of the same and intermediates for the synthesis thereof |
EP1314423A4 (en) * | 2000-09-01 | 2004-05-19 | Sankyo Co | Medicinal compositions |
JO2654B1 (en) | 2000-09-04 | 2012-06-17 | شركة جانسين فارماسوتيكا ان. في | Polyarylcarboxamides useful as lipid lowering agents |
EP1326835A1 (en) * | 2000-10-05 | 2003-07-16 | Fujisawa Pharmaceutical Co., Ltd. | Benzamide compounds as apo b secretion inhibitors |
JO2409B1 (en) | 2000-11-21 | 2007-06-17 | شركة جانسين فارماسوتيكا ان. في | Biphenylcarboxamides useful as lipid lowering agents |
US20040157866A1 (en) * | 2001-04-30 | 2004-08-12 | Hisashi Takasugi | Amide compounds |
ATE444060T1 (en) | 2001-06-22 | 2009-10-15 | Pfizer Prod Inc | PHARMACEUTICAL COMPOSITIONS CONTAINING DISPERSIONS OF MEDICINAL SUBSTANCES AND NEUTRAL POLYMERS |
AU2002307839B2 (en) | 2001-06-28 | 2006-03-16 | Zoetis P Llc | Triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (MTP) and/or apolipoprotein B (Apo B) secretion |
US20030144350A1 (en) * | 2001-07-20 | 2003-07-31 | Adipogenix, Inc. | Fat accumulation-modulation compounds |
WO2003013516A1 (en) * | 2001-08-10 | 2003-02-20 | Adipogenix, Inc. | Fat accumulation-modulating compounds |
JP2005510564A (en) * | 2001-11-28 | 2005-04-21 | 藤沢薬品工業株式会社 | Heterocyclic amide compounds as apolipoprotein B inhibitors |
CN1309370C (en) * | 2002-02-01 | 2007-04-11 | 辉瑞产品公司 | Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus |
KR100717098B1 (en) | 2002-02-28 | 2007-05-10 | 니뽄 다바코 산교 가부시키가이샤 | Ester compound and medicinal use thereof |
AU2003230665B2 (en) * | 2002-03-13 | 2010-02-18 | University Of Tennessee Research Foundation | Substituted tetrahydroisoquinoline compounds, methods of making, and their use |
WO2004039795A2 (en) * | 2002-10-29 | 2004-05-13 | Fujisawa Pharmaceutical Co., Ltd. | Amide compounds for the treatment of hyperlipidemia |
BR0317426A (en) * | 2002-12-20 | 2005-11-16 | Pfizer Prod Inc | Microsomal triglyceride transfer protein inhibitors |
BR0317323A (en) * | 2002-12-20 | 2005-11-16 | Pfizer Prod Inc | Microsomal Triglyceride Transfer Protein Inhibitors |
JP2006520810A (en) | 2003-03-17 | 2006-09-14 | 日本たばこ産業株式会社 | Method for increasing the oral absorption of S- [2-([[1- (2-ethylbutyl) cyclohexyl] carbonyl] amino) phenyl] 2-methylpropanethioate |
EP1669345A4 (en) | 2003-08-29 | 2008-02-20 | Japan Tobacco Inc | Ester derivative and medicinal use thereof |
SI1751111T1 (en) | 2004-03-01 | 2015-04-30 | Actelion Pharmaceuticals Ltd. | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives |
WO2005087234A1 (en) | 2004-03-05 | 2005-09-22 | The Trustees Of The University Of Pennsylvania | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects |
US7262318B2 (en) * | 2004-03-10 | 2007-08-28 | Pfizer, Inc. | Substituted heteroaryl- and phenylsulfamoyl compounds |
US20050288340A1 (en) * | 2004-06-29 | 2005-12-29 | Pfizer Inc | Substituted heteroaryl- and phenylsulfamoyl compounds |
US20060030623A1 (en) * | 2004-07-16 | 2006-02-09 | Noboru Furukawa | Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis |
US8101774B2 (en) * | 2004-10-18 | 2012-01-24 | Japan Tobacco Inc. | Ester derivatives and medicinal use thereof |
MX2007004973A (en) * | 2004-10-25 | 2007-06-14 | Japan Tobacco Inc | Solid medicinal preparation improved in solubility and stability and process for producing the same. |
CA2588087A1 (en) * | 2004-11-15 | 2006-05-18 | Obe Therapy Biotechnology S.A.S. | Methods of reducing body fat |
JP2006249022A (en) | 2005-03-11 | 2006-09-21 | Sumitomo Chemical Co Ltd | Method for producing 4-(2-methylphenyl)benzotrifluoride |
AU2006236226B2 (en) * | 2005-04-19 | 2012-07-05 | Surface Logix, Inc. | Inhibitors of microsomal triglyceride transfer protein and Apo-B secretion |
CA2609783A1 (en) * | 2005-05-27 | 2006-12-07 | Pfizer Products Inc. | Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss |
US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
US7919506B2 (en) | 2006-03-10 | 2011-04-05 | Pfizer Inc. | Dibenzyl amine compounds and derivatives |
AU2007225273A1 (en) * | 2006-03-10 | 2007-09-20 | Neurogen Corporation | Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues |
US8383660B2 (en) | 2006-03-10 | 2013-02-26 | Pfizer Inc. | Dibenzyl amine compounds and derivatives |
JP5814505B2 (en) | 2006-04-03 | 2015-11-17 | ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブRoche Innovation Center Copenhagen A/S | Pharmaceutical composition comprising antimiRNA antisense oligonucleotide |
EP3431602A1 (en) * | 2006-04-03 | 2019-01-23 | Roche Innovation Center Copenhagen A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
US20090042835A1 (en) * | 2006-06-02 | 2009-02-12 | Davis Roger A | Compositions and methods for ameliorating hyperlipidemia |
WO2007143164A1 (en) * | 2006-06-02 | 2007-12-13 | San Diego State University Research Foundation | Compositions and methods for ameliorating hyperlipidemia |
US20100216864A1 (en) * | 2006-10-09 | 2010-08-26 | Ellen Marie Straarup | RNA Antagonist Compounds for the Modulation of PCSK9 |
US20100210633A1 (en) * | 2006-10-12 | 2010-08-19 | Epix Delaware, Inc. | Carboxamide compounds and their use |
JO2653B1 (en) | 2006-10-24 | 2012-06-17 | شركة جانسين فارماسوتيكا ان. في | Piperidine Or Piperazine Substituted Tetrahydro-Naphthalene-1-Carboxylic Acid Mtp Inhibiting Compounds.apoB |
BRPI0717314A2 (en) | 2006-10-24 | 2014-01-21 | Janssen Pharmaceutica Nv | TETRAHYDRO-NAPHTHALENE-1-CARBOXYLIC ACID DERIVATIVES MTP INHIBITORS |
US8404896B2 (en) | 2006-12-01 | 2013-03-26 | Bristol-Myers Squibb Company | N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases |
WO2008075949A1 (en) * | 2006-12-20 | 2008-06-26 | Friesland Brands B.V. | Modulation of human microsomal triglyceride transfer protein (mtp or mttp) gene expression by food-grade/ingested dietary microorganisms |
EP2120927A1 (en) * | 2006-12-21 | 2009-11-25 | Aegerion Pharmaceuticals, Inc. | Methods for treating obesity with a combination comprising a mtp inhibitor and a cholesterol absorption inhibitor |
DK2149605T3 (en) * | 2007-03-22 | 2013-09-30 | Santaris Pharma As | Short RNA antagonist compounds to modulate the desired mRNA |
AU2008228243B2 (en) * | 2007-03-22 | 2014-05-15 | Santaris Pharma A/S | RNA antagonist compounds for the inhibition of Apo-B100 expression |
BRPI0813647A2 (en) * | 2007-06-25 | 2014-12-23 | Neurogen Corp | PIPERAZINIL OXOALQUIL TETRAHYDRO-BETA CARBOLINS AND RELATED ANALOGS |
US20110054011A1 (en) * | 2007-08-30 | 2011-03-03 | Mccullagh Keith | RNA Antagonist Compounds for the Modulation of FABP4/AP2 |
AU2008306327B2 (en) * | 2007-10-04 | 2014-05-15 | Roche Innovation Center Copenhagen A/S | Micromirs |
HUE028064T2 (en) | 2007-12-03 | 2016-11-28 | Obe Therapy Biotechnology | Boropeptide inhibitors of enteropeptidase and their uses in treatment of obesity, overweight and/or diseases associated with an abnormal fat metabolism |
US8569282B2 (en) | 2007-12-11 | 2013-10-29 | Cytopathfinder, Inc. | Carboxamide compounds and their use |
US20090197947A1 (en) * | 2008-02-01 | 2009-08-06 | The Research Foundation Of State University Of New York | Medicaments and methods for lowering plasma lipid levels and screening drugs |
US8404659B2 (en) * | 2008-03-07 | 2013-03-26 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of MicroRNA related diseases |
ES2541442T3 (en) | 2008-08-01 | 2015-07-20 | Roche Innovation Center Copenhagen A/S | MicroRNA-mediated modulation of colony stimulating factors |
WO2010122538A1 (en) * | 2009-04-24 | 2010-10-28 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon |
US8563528B2 (en) | 2009-07-21 | 2013-10-22 | Santaris Pharma A/S | Antisense oligomers targeting PCSK9 |
BR112015026513A2 (en) | 2013-04-17 | 2017-07-25 | Pfizer | n-piperidin-3-ylbenzamide derivatives to treat cardiovascular disease |
CN112263682A (en) | 2013-06-27 | 2021-01-26 | 罗氏创新中心哥本哈根有限公司 | Antisense oligomers and conjugates targeting PCSK9 |
US9856478B2 (en) | 2013-10-30 | 2018-01-02 | Trustees Of Dartmouth College | Method for selectively inhibiting ACAT1 in the treatment of obesity, metabolic syndrome, and atherosclerosis |
WO2016055901A1 (en) | 2014-10-08 | 2016-04-14 | Pfizer Inc. | Substituted amide compounds |
CA2965336A1 (en) * | 2014-10-22 | 2016-04-28 | The Board Of Regents Of The University Of Texas System | Small-molecule inhibitors targeting discoidin domain receptor 1 and uses thereof |
MX2021008533A (en) | 2019-01-18 | 2021-08-19 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof. |
CN113292493A (en) * | 2021-06-23 | 2021-08-24 | 上海立科化学科技有限公司 | Preparation method of 5, 7-dichloro-1, 2,3, 4-tetrahydroisoquinoline |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4022900A (en) * | 1970-09-09 | 1977-05-10 | Marion Laboratories, Inc. | Compositions containing 1,2,3,4-tetrahydroisoquinolines used as hypotensive agents |
EP0643057A1 (en) * | 1993-09-03 | 1995-03-15 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein |
WO1996026205A1 (en) * | 1995-02-21 | 1996-08-29 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996040640A1 (en) * | 1995-06-07 | 1996-12-19 | Pfizer Inc. | BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION |
-
1997
- 1997-11-03 YU YU23499A patent/YU23499A/en unknown
- 1997-11-03 SK SK654-99A patent/SK65499A3/en unknown
- 1997-11-03 JP JP52446498A patent/JP3270764B2/en not_active Expired - Fee Related
- 1997-11-03 TR TR1999/01180T patent/TR199901180T2/en unknown
- 1997-11-03 NZ NZ335162A patent/NZ335162A/en unknown
- 1997-11-03 BR BR9714364A patent/BR9714364A/en not_active Application Discontinuation
- 1997-11-03 CN CN97180033A patent/CN1238764A/en active Pending
- 1997-11-03 IL IL12974497A patent/IL129744A0/en unknown
- 1997-11-03 AU AU46347/97A patent/AU716151B2/en not_active Ceased
- 1997-11-03 KR KR1019997004662A patent/KR100334567B1/en not_active IP Right Cessation
- 1997-11-03 CA CA002272719A patent/CA2272719C/en not_active Expired - Fee Related
- 1997-11-03 EA EA199900416A patent/EA001539B1/en not_active IP Right Cessation
- 1997-11-03 EP EP97945048A patent/EP0944602A1/en not_active Withdrawn
- 1997-11-03 US US09/284,466 patent/US6121283A/en not_active Expired - Fee Related
- 1997-11-03 WO PCT/IB1997/001368 patent/WO1998023593A1/en not_active Application Discontinuation
- 1997-11-04 HN HN1997000144A patent/HN1997000144A/en unknown
- 1997-11-05 TW TW086116476A patent/TW502023B/en not_active IP Right Cessation
- 1997-11-14 PA PA84416A patent/PA8441601A1/en unknown
- 1997-11-20 AP APAP/P/1997/001145A patent/AP804A/en active
- 1997-11-24 PE PE1997001062A patent/PE17199A1/en not_active Application Discontinuation
- 1997-11-25 GT GT199700122A patent/GT199700122A/en unknown
- 1997-11-25 UY UY24789A patent/UY24789A1/en not_active Application Discontinuation
- 1997-11-25 ID IDP973763A patent/ID18995A/en unknown
- 1997-11-26 ZA ZA9710641A patent/ZA9710641B/en unknown
- 1997-11-26 TN TNTNSN97193A patent/TNSN97193A1/en unknown
- 1997-11-26 DZ DZ970208A patent/DZ2358A1/en active
- 1997-11-26 AR ARP970105560A patent/AR010309A1/en unknown
- 1997-11-26 HR HR60/032,307A patent/HRP970642A2/en not_active Application Discontinuation
- 1997-11-26 MA MA24877A patent/MA26451A1/en unknown
-
1999
- 1999-04-30 IS IS5040A patent/IS5040A/en unknown
- 1999-05-19 OA OA9900106A patent/OA11050A/en unknown
- 1999-05-26 BG BG108830A patent/BG108830A/en unknown
- 1999-05-26 BG BG103434A patent/BG103434A/en unknown
- 1999-05-26 NO NO19992525A patent/NO312760B1/en unknown
-
2002
- 2002-02-19 CN CN02105189A patent/CN1380289A/en active Pending
- 2002-09-17 CZ CZ20023137A patent/CZ292160B6/en not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4022900A (en) * | 1970-09-09 | 1977-05-10 | Marion Laboratories, Inc. | Compositions containing 1,2,3,4-tetrahydroisoquinolines used as hypotensive agents |
EP0643057A1 (en) * | 1993-09-03 | 1995-03-15 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein |
WO1996026205A1 (en) * | 1995-02-21 | 1996-08-29 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AP804A (en) | APO-B-secretion/MTP inhibitory amides. | |
KR101186386B1 (en) | Compound capable of binding s1p receptor and pharmaceutical use thereof | |
US6121304A (en) | Pentafluorobenzenesulfonamides and analogs | |
JP5989923B2 (en) | Methyl group-modifying enzyme regulator, composition and use thereof | |
US7291644B2 (en) | Indole derivatives | |
EP2593428B1 (en) | N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels | |
JP6866514B2 (en) | PPAR agonists, compounds, pharmaceutical compositions, and how to use them | |
McKew et al. | Indole Cytosolic Phospholipase A2 α Inhibitors: Discovery and in Vitro and in Vivo Characterization of 4-{3-[5-Chloro-2-(2-{[(3, 4-dichlorobenzyl) sulfonyl] amino} ethyl)-1-(diphenylmethyl)-1 H-indol-3-yl] propyl} benzoic Acid, Efipladib | |
AU2015219920B2 (en) | Triazine compound and use thereof for medical purposes | |
JP2007501263A (en) | N-acyl nitrogen heterocycles as ligands for peroxisome proliferator-activated receptors | |
TW200408393A (en) | Antagonist of lysophosphatidine acid receptor | |
EP2424517A1 (en) | Sulfamoyl benzoic acid derivatives as trpm8 antagonists | |
CN101146530A (en) | 3, 4-substituted pyrrolidine derivatives for the treatment of hypertension | |
CN101223140A (en) | Piperidine derivatives useful in the diagnostic and therapeutic treatment of diseases depending on renin activity | |
US7135495B2 (en) | Indole derivatives | |
Yuan et al. | Discovery of 2-azetidinone and 1H-pyrrole-2, 5-dione derivatives containing sulfonamide group at the side chain as potential cholesterol absorption inhibitors | |
KR20200015888A (en) | Amide Derivatives Used as Nav1.7 and Nav1.8 Blockers | |
WO2016055901A1 (en) | Substituted amide compounds | |
He et al. | Design, synthesis and molecular docking of amide and urea derivatives as Escherichia coli PDHc-E1 inhibitors | |
Wang et al. | Synthesis and biological evaluation of ezetimibe analogs as possible cholesterol absorption inhibitors | |
Takahashi et al. | Novel indoline-based acyl-CoA: cholesterol acyltransferase inhibitor with antiperoxidative activity: improvement of physicochemical properties and biological activities by introduction of carboxylic acid | |
CN1227008C (en) | Converting COX-2 inhibition compounds that are not COX-2 selective inhibitors to derivatives that are COX-2 selective inhibitors | |
US6762182B1 (en) | Converting cox inhibition compounds that are not COX-2 selective inhibitors to derivatives that are COX-2 selective inhibitors | |
US11261154B2 (en) | Benzene derivative | |
Yang et al. | Discovery of Novel N-Hydroxy-1, 2, 4-oxadiazole-5-formamides as ASM Direct Inhibitors for the Treatment of Atherosclerosis |